Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Sep-30-16 | Jun-30-16 | Mar-31-16 | Dec-31-15 | Sep-30-15 | Jun-30-15 | Mar-31-15 | Dec-31-14 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues: |
| Traditional Wound Care | 6.0 | 11.2 | 9.6 | | 6.4 | 12.3 | 9.7 | 11.4 |
| Advanced Wound Care | 15.8 | 11.0 | 10.6 | | 11.3 | 10.3 | 9.8 | 11.5 |
| Other | 1.3 | | | | 0.9 | | | |
| Total revenues | 21.8 | 22.2 | 20.2 | 20.3 | 17.8 | 22.6 | 19.5 | 22.9 |
| Revenue growth [+] | 22.6% | -1.5% | 3.8% | -11.5% | -11.8% | 7.8% | -1.5% | 10.5% |
| Traditional Wound Care | -6.5% | -8.4% | -0.9% | | | 1.3% | | |
| Advanced Wound Care | 39.1% | 6.6% | 8.5% | | | 16.8% | | |
| Other | 47.1% | | | | | | | |
| Cost of goods sold | 11.1 | 13.9 | 12.5 | 11.9 | 10.5 | 14.2 | 12.0 | 13.9 |
| Gross profit | 10.7 | 8.3 | 7.7 | 8.4 | 7.3 | 8.4 | 7.5 | 9.0 |
| Gross margin | 49.1% | 37.2% | 38.1% | 41.4% | 41.0% | 37.1% | 38.6% | 39.3% |
| Selling, general and administrative | 13.7 | 10.3 | 10.0 | -1.5 | 12.2 | 13.7 | 13.3 | 12.3 |
| Research and development | 0.1 | | | | 0.1 | 0.2 | 0.4 | 6.3 |
| EBITDA [+] | | | | | | | | -7.8 |
| EBITDA growth | -56.4% | -72.5% | -71.9% | -235.6% | -58.3% | -42.6% | -44.5% | 87.2% |
| EBITDA margin | -8.6% | -6.0% | -7.4% | 52.4% | -24.2% | -21.3% | -27.3% | -34.2% |
| Depreciation | | | | | | | | 0.9 |
| EBITA | -1.9 | -1.3 | -1.5 | 10.6 | -4.3 | -4.8 | -5.3 | -8.7 |
| EBITA margin | -8.6% | -6.0% | -7.4% | 52.4% | -24.2% | -21.3% | -27.3% | -38.0% |
| Amortization of intangibles | 1.2 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 |
| EBIT [+] | -3.1 | -2.0 | -2.2 | 9.9 | -5.1 | -5.6 | -6.1 | -9.5 |
| EBIT growth | -39.4% | -63.6% | -63.0% | -203.5% | -54.5% | -39.2% | -41.1% | 88.1% |
| EBIT margin | -14.1% | -9.1% | -11.1% | 48.7% | -28.4% | -24.7% | -31.2% | -41.7% |
| Non-recurring items [+] | 2.7 | | | 2.5 | | | | |
| Restructuring charges | 2.7 | | | | | | | |
| Other income (expense), net [+] | -0.2 | 4.5 | 0.3 | -0.5 | -0.7 | 0.9 | -0.4 | 0.1 |
| Other | -0.2 | -4.5 | -0.3 | 0.5 | -0.7 | -0.9 | 0.4 | -0.1 |
| Pre-tax income | -6.0 | 2.5 | -2.0 | 6.9 | -5.7 | -4.7 | -6.4 | -9.5 |
| Income taxes | -1.5 | 0.5 | -0.2 | -1.6 | -1.1 | 0.3 | 0.0 | 0.1 |
| Tax rate | 24.2% | 21.0% | 11.1% | | 18.4% | | | |
| Minority interest | | | | -17.7 | | | | |
| Earnings from continuing ops | -4.6 | 2.0 | -1.8 | 8.5 | -4.7 | -5.0 | -6.5 | -9.6 |
| Earnings from discontinued ops | 3.8 | | | | | | | |
| Net income | -1.4 | 2.0 | -1.8 | -9.2 | -9.0 | -9.3 | -10.6 | -9.6 |
| Net margin | -6.4% | 8.9% | -8.7% | -45.7% | -50.4% | -41.2% | -54.4% | -41.8% |
| |
| Basic EPS [+] | ($0.17) | $0.08 | ($0.07) | $0.33 | ($0.18) | ($0.20) | ($0.25) | ($0.39) |
| Growth | -7.3% | -139.2% | -73.1% | -184.8% | -59.3% | -43.4% | -44.5% | 22.3% |
| Diluted EPS [+] | ($0.17) | $0.08 | ($0.07) | $0.33 | ($0.18) | ($0.20) | ($0.25) | ($0.39) |
| Growth | -7.3% | -139.0% | -73.1% | -184.8% | -59.3% | -43.4% | -44.5% | 22.3% |
| |
| Shares outstanding (basic) [+] | 27.2 | 25.9 | 25.9 | 25.7 | 25.8 | 25.8 | 25.6 | 24.6 |
| Growth | 5.6% | 0.6% | 1.3% | 4.7% | 2.2% | 2.2% | 13.2% | 44.1% |
| Shares outstanding (diluted) [+] | 27.2 | 26.1 | 25.9 | 25.7 | 25.8 | 25.8 | 25.6 | 24.6 |
| Growth | 5.6% | 1.2% | 1.3% | 4.7% | 2.2% | 2.2% | 13.2% | 44.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|